Abstract
AbstractBenjamin Ayres discusses the use of BCG in the management of non‐muscle‐invasive bladder cancer, emphasising the importance of controlling the inevitable side‐effects of this toxic treatment. Copyright © 2013 John Wiley & Sons
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have